Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The spread of pandemic H1N1 2009 by age and region and the comparison among monitoring tools.

Kim JH, Yoo HS, Lee JS, Lee EG, Park HK, Sung YH, Kim S, Kim HS, Shin SY, Lee JK.

J Korean Med Sci. 2010 Jul;25(7):1109-12. doi: 10.3346/jkms.2010.25.7.1109. Epub 2010 Jun 17.

3.

Incidence of medically attended influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009-13.

Fowlkes A, Steffens A, Temte J, Di Lonardo S, McHugh L, Martin K, Rubino H, Feist M, Davis C, Selzer C, Lojo J, Oni O, Kurkjian K, Thomas A, Boulton R, Bryan N, Lynfield R, Biggerstaff M, Finelli L; Influenza Incidence Surveillance Project Working Group.

Lancet Respir Med. 2015 Sep;3(9):709-18. doi: 10.1016/S2213-2600(15)00278-7. Epub 2015 Aug 21.

PMID:
26300111
4.

A review of the dynamics and severity of the pandemic A(H1N1) influenza virus on Réunion island, 2009.

D'Ortenzio E, Renault P, Jaffar-Bandjee MC, Gaüzère BA, Lagrange-Xélot M, Fouillet A, Poubeau P, Winer A, Bourde A, Staikowsky F, Morbidelli P, Rachou E, Thouillot F, Michault A, Filleul L.

Clin Microbiol Infect. 2010 Apr;16(4):309-16. doi: 10.1111/j.1469-0691.2010.03171.x. Epub 2010 Jan 28.

5.

Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study.

Donaldson LJ, Rutter PD, Ellis BM, Greaves FE, Mytton OT, Pebody RG, Yardley IE.

BMJ. 2009 Dec 10;339:b5213.

6.

Effect of vaccines and antivirals during the major 2009 A(H1N1) pandemic wave in Norway--and the influence of vaccination timing.

Blasio BF, Iversen BG, Tomba GS.

PLoS One. 2012;7(1):e30018. doi: 10.1371/journal.pone.0030018. Epub 2012 Jan 10.

7.

Impact of antiviral treatment and hospital admission delay on risk of death associated with 2009 A/H1N1 pandemic influenza in Mexico.

Chowell G, Viboud C, Simonsen L, Miller MA, Echevarría-Zuno S, González-León M, Aburto VH.

BMC Infect Dis. 2012 Apr 20;12:97.

8.

Vaccines against influenza A (H1N1) pandemic.

Valdespino-Gomez JL, Garcia-Garcia L, de León-Rosales SP.

Arch Med Res. 2009 Nov;40(8):693-704. doi: 10.1016/j.arcmed.2009.10.008.

PMID:
20304259
9.

Influenza--interpandemic as well as pandemic disease.

Dolin R.

N Engl J Med. 2005 Dec 15;353(24):2535-7. No abstract available.

PMID:
16354889
10.

Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study.

Sachedina N, Donaldson LJ.

Lancet. 2010 Nov 27;376(9755):1846-52. doi: 10.1016/S0140-6736(10)61195-6. Epub 2010 Oct 26.

11.

Nationwide surveillance of influenza during the pandemic (2009-10) and post-pandemic (2010-11) periods in Taiwan.

Chuang JH, Huang AS, Huang WT, Liu MT, Chou JH, Chang FY, Chiu WT.

PLoS One. 2012;7(4):e36120. doi: 10.1371/journal.pone.0036120. Epub 2012 Apr 24.

12.

Epidemiological characteristics of novel influenza A (H1N1) in antiviral drug users in Korea.

Choi K, Cho SI, Hashizume M, Kim H.

PLoS One. 2012;7(10):e47634. doi: 10.1371/journal.pone.0047634. Epub 2012 Oct 17.

13.

[Mathematical modeling of the novel influenza A (H1N1) virus and evaluation of the epidemic response strategies in the Republic of Korea].

Suh M, Lee J, Chi HJ, Kim YK, Kang DY, Hur NW, Ha KH, Lee DH, Kim CS.

J Prev Med Public Health. 2010 Mar;43(2):109-16. doi: 10.3961/jpmph.2010.43.2.109. Korean.

14.

Epidemiological characteristics of pandemic influenza A (H1N1-2009) in Zhanjiang, China.

Fu J, Chen S, Chen J, Wang J, Ling C.

Pan Afr Med J. 2011;10:54. Epub 2011 Dec 14.

15.

U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic.

Borders-Hemphill V, Mosholder A.

Influenza Other Respir Viruses. 2012 Nov;6(6):e129-33. doi: 10.1111/j.1750-2659.2012.00384.x. Epub 2012 Jun 9.

16.

A new sentinel surveillance system for severe influenza in England shows a shift in age distribution of hospitalised cases in the post-pandemic period.

Bolotin S, Pebody R, White PJ, McMenamin J, Perera L, Nguyen-Van-Tam JS, Barlow T, Watson JM; UK Severe Influenza Surveillance System (USISS) Steering Group.

PLoS One. 2012;7(1):e30279. doi: 10.1371/journal.pone.0030279. Epub 2012 Jan 23.

17.

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.

Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, Crowcroft N, Kwindt TL, Tang P, Charest H, Fonseca K, Gubbay JB, Bastien N, Li Y, Petric M.

BMJ. 2011 Feb 3;342:c7297. doi: 10.1136/bmj.c7297.

18.

Overview/reflections on the 2009 H1N1 pandemic.

Pada S, Tambyah PA.

Microbes Infect. 2011 May;13(5):470-8. doi: 10.1016/j.micinf.2011.01.009. Epub 2011 Jan 27. Review.

PMID:
21276873
19.

Spatial and temporal characteristics of the 2009 A/H1N1 influenza pandemic in Peru.

Chowell G, Viboud C, Munayco CV, Gómez J, Simonsen L, Miller MA, Tamerius J, Fiestas V, Halsey ES, Laguna-Torres VA.

PLoS One. 2011;6(6):e21287. doi: 10.1371/journal.pone.0021287. Epub 2011 Jun 21.

20.

Influenza pandemic (H1N1) 2009 activity during summer 2009. Effectiveness of the 2008-9 trivalent vaccine against pandemic influenza in Spain.

Larrauri A, Savulescu C, Jiménez-Jorge S, Pérez-Breña P, Pozo F, Casas I, Ledesma J, de Mateo S; Spanish Influenza Surveillance System (SISS).

Gac Sanit. 2011 Jan-Feb;25(1):23-8. doi: 10.1016/j.gaceta.2010.06.010. Epub 2011 Feb 22.

Supplemental Content

Support Center